Stock profile
- Symbol
- LLY
- Listing
- NYSE
- Sector
- Healthcare
- Currency
- USD
- Analyses published
- 2
- First analysis
Latest analysis ·
Eli Lilly stock stalls near $1,140 as Foundayo grabs 30% of new obesity-drug patients
Eli Lilly stock presents conflicting signals across timeframes. The daily chart shows cooling, while the hourly hints at stabilization. Meanwhile, Berenberg upgraded LLY on obesity drug strength, as Foundayo captured over 30% of new U.S. oral GLP-1 patients — directly challenging Novo Nordisk. The technical…
About Eli Lilly
Eli Lilly is one of the world’s largest pharmaceutical companies, founded in Indianapolis in 1876 by Colonel Eli Lilly and still based in Indiana. It is listed on the New York Stock Exchange. It develops and manufactures drugs in several areas, including diabetes, obesity, oncology and immunology. It is a leading player in diabetes and obesity treatments, with products such as Mounjaro and Zepbound based on tirzepatide. It also has a long history in insulin.
What moves the stock
Eli Lilly stock depends on sales of its main drugs, on quarterly earnings and on clinical trials of new molecules. Approvals by authorities such as the FDA, manufacturing capacity for obesity drugs and competition from other producers matter. Reimbursement and prices negotiated with insurers and governments, patent expirations, U.S. health policy and interest rates, which affect valuations of large growth companies, also weigh.
How to read Cryptonomist’s analyses
Clinical trials and sales of the main drugs drive Eli Lilly, in a sector where news often comes while markets are closed, so the opening gap is information in itself. Obesity drugs and trial outcomes are the themes on which the market is split, and the daily chart shows whether the consensus holds. The session should be checked before using the levels. An overnight release on a trial’s outcome often turns into a gap, and the hourly and 15-minute charts show whether the opening move was kept or scaled back during the day.
All analyses on Eli Lilly
Other stocks
Informational content, not financial advice or an invitation to invest.
